×
Transformational merger ahead: The planned combination with Treeline is the defining catalyst, shifting Standard BioTools toward a catalyst-rich, well-capitalized therapeutics pipeline and away from its legacy tools-only profile. Leaner operating model: A restructuring that consolidated research and development (R&D) in Singapore and relocated headquarters to Boston has sharply narrowed losses, with management targeting positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) by the end of 2026.
Margin expansion is the central 2026 theme: Management guides to 3%–4% organic revenue growth and adjusted EBIT (earnings before interest and taxes) margin of 15.8%–16.1%, implying 50–80 basis points of expansion. Radiopharmaceuticals momentum: Pharmaceutical Diagnostics delivered double-digit growth in late 2025, with newer agents such as Flyrcado positioned as growth catalysts ahead.
The central target of $89 is the arithmetic mean of 10 recently published, individually attributed analyst price targets, rounded from roughly $88.90. At the latest close near $80.84, reaching $89 implies upside of about 10%, a modest move by conventional standards.
Standard BioTools (LAB) shares have traded in a roughly flat-to-lower range over the trailing 30 days, holding near $0.63 despite sharp intraday swings. Stockholders approved the all-stock merger with Treeline Biosciences and the sale of the Mass Cytometry business to Element Biosystems on November 19, 2026.
GE HealthCare (GEHC) shares advanced about 12.9% over the last 30 days, climbing from a closing price of $71.42 on October 22 to $80.64 on November 20. The move was fueled largely by a stronger-than-expected Q3 2026 earnings report, with adjusted EPS of $1.34 beating the roughly $1.21 consensus and revenue rising 7.2% year over year.
PROF shares have climbed roughly 13% over the last 30 days, recovering from about $5.69 to near $6.44. The advance was fueled by record preliminary third-quarter revenue, a raised full-year revenue outlook, and a new U.S. distribution agreement with Cook Medical's iMRI division.
Quanterix Corporation ( QTRX ) is navigating a commercial turnaround in precision diagnostics and research tools, while Twist Bioscience ( TWST ) is riding an AI-enabled drug discovery growth cycle. TWST delivered 28% year-over-year revenue growth and its first positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) quarter in recent results, versus a 13% revenue decline for QTRX .
Neuronetics shares fell roughly 42% over the past 30 days, sliding from a $2.01 close on October 21, 2026, to about $1.16 in recent trading. A heavily discounted public offering of 18.75 million common shares at $1.60 per share triggered the steepest leg of the decline, diluting existing shareholders.
CATX (Perspective Therapeutics) is a clinical-stage radiopharmaceutical developer; STRR (Star Equity Holdings) is a diversified micro-cap holding company, making this a contrast between a high-catalyst biotech and an asset-heavy conglomerate. Both names carry weak fundamentals and persistent net losses, but STRR has shown relatively greater price stability and insider/activist support in recent weeks.
Perspective Therapeutics (CATX) shares declined roughly 67% over the trailing 30 days, falling from about $2.30 to around $0.77. The selloff was triggered by interim Phase 1/2a data for its lead candidate VMT-α-NET, presented at the ESMO Congress 2026, which came in below investor expectations.
Two very different risk profiles: ITGR is a cash-generating medical device manufacturer in a pending acquisition, while TWST is a high-growth, unprofitable synthetic biology company riding an AI-driven rally. Relative performance has diverged sharply: TWST has roughly quadrupled over the past year on AI drug discovery momentum, whereas ITGR spent recent quarters under pressure from softer customer forecasts before a takeover bid emerged.
10x Genomics shares rose to $59.26 on Thursday afternoon, up +$2.19, or +3.84%, from Wednesday's close of $57.07, with the gain occurring during regular-session trading after a higher premarket indication. No verified news or fundamental catalyst found — no filing, guidance update or analyst action accompanied the move. The advance is consistent with a rebound in an oversold stock: TXG is -19% over the past month and trades below its 50-day average, while its average daily swing is about 4.2%.
CTKB jumped +5.74% to $6.26 from the previous close of $5.92, with the move taking place during Thursday's regular session after a firm premarket indication. No verified news or fundamental catalyst found. The gain is likely momentum-driven buying in a thinly traded small-cap: shares had already climbed +13% from the Nov 12 close of $5.52 and are pressing the 52-week high of $6.34, while the stock's typical session swing is about 2.5%.
QTRX fell -11.59% in regular trading on Nov 19, dropping from $2.07 at the prior close to $1.825 midday, extending a two-session slide that has cut -36% from the shares. The move extends the selloff that started before the Nov 18 open, when Quanterix announced CEO Everett Cunningham had stepped down immediately after 10 months, naming Chief Commercial Officer Jim Gute interim CEO; no fresh company news has followed.
CV fell -5.72% during Thursday's regular session, sliding to $6.43 from the prior close of $6.82, a decline of -$0.39 recorded in early trading. No verified news or fundamental catalyst found. The drop is likely profit-taking after three straight up sessions added +13% (from $6.03 to $6.82), with the stock averaging a 2.6% absolute daily swing and 8 of the last 60 sessions matching or exceeding today's move.
Mobia Medical shares fell from a $13.03 close to $12.14, a move of -6.83%, during Thursday's regular session, with the decline already in place in mid-morning trading. No verified news or fundamental catalyst found: no company release, filing, or analyst action accompanied the drop. The pullback is most likely profit-taking after a +48% run from the October 19 low near $8.03, a pattern consistent with a thin-float micro-cap retracing part of a steep advance.
Commercial inflection point: The FDA 510(k)-cleared Nanox.ARC X system is entering a global deployment phase, positioning Nano-X Imaging to move from pre-revenue hardware to scaled commercial sales. Deployment momentum: Management has guided for more than 100 clinical, demonstration, and commercial units in various stages of rollout worldwide by the end of 2025, a metric closely watched by investors.
Nano-X Imaging (NNOX) fell roughly 36.8% over the last 30 days, sliding from about $0.41 to near $0.26, extending a prolonged downtrend. The decline reflects persistent dilution concerns, a pending reverse-split proposal, and disclosed uncertainty about the company's ability to continue as a going concern.
RCEL jumped +8.43% to $17.10 from the prior close of $15.77, with the gain occurring during regular trading hours on November 18. No verified news or fundamental catalyst found: the last company release, full Cohealyx I six-month data on November 16, preceded a -2.6% decline, so today's move is likely a rebound after a four-session slide of roughly -14% from $17.65, in a micro-cap that averages a 3.2% daily swing and is up more than +300% over twelve months.
VNRX fell -5.26% to $0.18 from the prior close of $0.19, with the drop coming during regular trading hours after an early premarket gain of about +3% reversed. No verified news or fundamental catalyst found for today's session — no new filing, release or financing since the Q3 update — and the slide is consistent with continued unwinding of the November 13 earnings-day spike of +24.7%, in a stock that has averaged a 5.9% daily swing over the past 60 sessions.